查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症遗传基因面板检验和分析市场:各癌症类型，各用途，不同组织，各遗传基因类型，潜在的市场筛检，市场规模 - 高级顾问指南（2026-2030）
市场调查报告书
商品编码
1826001

癌症遗传基因面板检验和分析市场:各癌症类型，各用途，不同组织，各遗传基因类型，潜在的市场筛检，市场规模 - 高级顾问指南（2026-2030）

Genomic Cancer Panel and Profiling Markets by Cancer, by Application, by Tissue and by Gene Type with Screening Potential Market Size. With Executive and Consultant Guides 2026 -2030
出版日期: | 出版商: Howe Sound Research | 英文 593 Pages | 商品交期: 最快1-2个工作天内

价格

报告概述

癌症基因组合和基因分析正在迅速改变癌症的诊断和治疗。如今，人工智慧正在开启新的大门。随着肿瘤学家开始常规使用数百种癌症相关基因的信息，该市场正从专业领域走向主流。该市场在两个不同的领域正经历爆炸性成长。了解这种理解癌症的新方法将如何彻底改变癌症诊断。

了解参与者如何在从零开始创建的市场中争夺地位，包括综合组合、基因分析和高风险乳癌组合。一些参与者正在获得显着的领先优势并在全球扩张。这是一个充满活力的市场，蕴藏着巨大的机遇，合适的诊断方法和合适的支持能够带来溢价。随着科学的发展，新的机会层出不穷。测序成本持续下降。

本报告包​​含18个国家/地区和4个地区的详细分析。购买本报告的用户将获得全球各国的详细分析。

目录

第1章 市场指南

  • 癌症基因组合市场 - 策略性情势分析
  • 大规模综合癌症基因组合市场 - 现况分析
  • 高阶主管、行销、销售和业务开发人员指南
  • 管理顾问和投资顾问指南
  • 人工智慧对癌症分析市场的影响

第2章 简介与市场定义

  • 什么是癌症基因组合与分析？
  • 定序革命
  • 市场定义
  • 研究方法
  • 视角：医疗保健支出

第3章 市场概要

  • 市场参与企业
    • 学术研究机构
    • 诊断测试开发商
    • 测量设备供应商
    • 药品和试剂製造商
    • 病理供应商
    • 独立临床实验室
    • 公共国家/地区实验室
    • 医院实验室
    • 临床实验室
    • 审计机构
    • 认证机构
  • 肿瘤基因体学
    • 致癌性
    • 污染染色体、基因和表观遗传学
    • 致癌基因
    • 生殖系与体细胞
    • 基因组合、单基因检测与多重分析
    • 基因组分析
    • 综合检测
    • 不断变化的临床角色
    • 癌症检测市场机遇
  • 癌症管理与诊断
    • 风险评估的作用
    • 诊断
    • 管理
    • 监测
  • 实施阶段展望
  • 对产业结构的影响
  • 目前可用的大规模综合检测
  • 分析和全外显子组（或基因组）定序的定价

第4章 市场趋势

  • 成长促进因素
    • 照护的层级
    • 伴同性Dx
    • 免疫肿瘤学
    • 责任
    • 老化的影响
  • 阻碍成长的要素
    • 知识的状态
    • 遗传基因雪夹冰
    • 通讯协定反抗
    • 法规与适用范围
  • 测量与自动化
  • 诊断技术开发

第5章 癌症面板和简介的最近趋势

第6章 主要企业简介

  • 10x Genomics, Inc.
  • Abbott Laboratories
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Admera Health, LLC
  • Aethlon Medical
  • Agilent
  • Amoy Diagnostics Co., Ltd.
  • Anchor Dx
  • ANGLE plc
  • ARUP Laboratories
  • AVIVA Systems Biology
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter Diagnostics(Danaher)
  • Becton, Dickinson and Company
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc.
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • BioIVT
  • Biolidics Ltd
  • bioMerieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bristol-Myers Squibb
  • Burning Rock
  • C2i Genomics
  • Cardiff Oncology
  • Caris Molecular Diagnostics
  • Castle Biosciences, Inc.
  • Celemics
  • CellMax Life
  • Cepheid(Danaher)
  • Charles River Laboratories
  • Circulogene
  • Clearbridge Biomedics
  • Clinical Genomics
  • Cytolumina Technologies Corp.
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Element Biosciences
  • Enzo Biochem
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exact Sciences
  • Fabric Genomics
  • Fluxion Biosciences(Cell Microsystems)
  • Freenome
  • FUJIFILM Wako Diagnostics
  • Fujirebio
  • GeneDx Holdings
  • GeneFirst Ltd.
  • Genetic Technologies Ltd.
  • Genetron Holdings
  • GenomOncology
  • GILUPI Nanomedizin
  • Guardant Health
  • HansaBiomed
  • HTG Molecular Diagnostics
  • iCellate
  • ICON PLC
  • Illumina
  • Incell Dx
  • Inivata
  • Invitae Corporation
  • Invivogen
  • Invivoscribe
  • J&J Innovative Medicine
  • KEW
  • Lucence Health
  • Lunglife AI Inc
  • MDNA Life SCIENCES, Inc.
  • MDx Health
  • Menarini Silicon Biosystems
  • Mesa Laboratories, Inc.
  • Millipore Sigma
  • Miltenyi Biotec
  • miR Scientific
  • Myriad Genetics
  • Nanostring
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • NGeneBio
  • Novogene
  • Oncimmune
  • Oncocyte
  • OncoDNA
  • OraLiva
  • Oxford Nanopore Technologies
  • Panagene
  • Personalis
  • Perthera
  • PGDx(Labcorp)
  • Precipio
  • PrecisionMed
  • Predictive Oncology
  • Prenetics
  • Promega
  • Qiagen
  • QuidelOrtho
  • Rarecells SAS
  • RareCyte
  • Revvity
  • Roche Diagnostics
  • Screencell
  • Sherlock Biosciences
  • Siemens Healthineers
  • simfo GmbH
  • Singlera Genomics Inc.
  • Singular Genomics
  • Singulomics
  • SkylineDx
  • Standard BioTools
  • Stilla Technologies
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific
  • Todos Medical
  • Ultima Genomics
  • Variantyx
  • Vela Diagnostics
  • Veracyte
  • VolitionRX
  • Vortex Biosciences

第7章 全球癌症遗传基因面板和简介市场

  • 各国全球市场概要
  • 全球市场- 概要，各癌症类型
  • 全球市场- 概要，各用途
  • 全球市场- 概要，不同组织
  • 全球市场- 概要，生殖细胞株及体细胞系

第8章 全球癌症遗传基因面板和简介市场- 各癌症类型

  • 全面的面板和简介
  • 乳癌
  • 大肠癌症
  • 妇产科癌症
  • 血液癌症
  • 前列腺癌症
  • 肺癌症
  • 其他

第9章 全球癌症遗传基因面板和简介市场- 各用途

  • 临床试验
  • 医药品实验
  • 研究实验

第10章 全球癌症遗传基因面板与简介市场- 各组织类型

  • 固态组织
  • 液体组织

第11章 全球癌症遗传基因检验市场- 生殖细胞株及体细胞系

  • 体细胞系
  • 生殖细胞株

第12章 潜在的市场机会的规模

  • 各国潜在的癌症筛检:肺癌症，乳癌，大肠癌症
  • 各国潜在的癌症筛检:前列腺癌症，其他的癌症，及的全部的癌症
  • 潜在市场规模- 癌症诊断
  • 潜在市场规模- 治疗方法的选择

第13章 附录

Report Overview:

Cancer Gene Panels and Genomic Profiling are quickly changing the diagnosis and treatment of cancers. And now Artificial Intelligence is opening new doors. The market is moving out of a specialized niche and going mainstream as Oncologists begin routinely using information on the hundreds of genes related to cancer. The market is exploding in two distinct segments. Find out how this new way of understanding cancer will change cancer diagnostics forever.

Comprehensive panels, genomic profiling, high risk breast cancer panels. Learn all about how players are jockeying for position in a market that is being created from scratch. And some players are pulling way out in front and expanding globally. It is a dynamic market situation with enormous opportunity where the right diagnostic with the right support can command premium pricing. And the science is developing at the same time creating new opportunities with regularity. And the cost of sequencing continues to fall.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Table of Contents

1. Market Guides

  • 1.1. Cancer Panel Market - Strategic Situation Analysis
  • 1.2. Large Comprehensive Cancer Panel Market - Situation Analysis
  • 1.3. Guide for Executives, Marketing, Sales and Business Development Staff
  • 1.4. Guide for Management Consultants and Investment Advisors
  • 1.5. Impact of Artificial Intelligence on Cancer Profiling Market

2. Introduction and Market Definition

  • 2.1. What are Cancer Gene Panels and Profiling?
  • 2.2. The Sequencing Revolution
  • 2.3. Market Definition
    • 2.3.1. Revenue Market Size
  • 2.4. Methodology
    • 2.4.1. Methodology
    • 2.4.2. Sources
    • 2.4.3. Authors
  • 2.5. Perspective: Healthcare Spending
    • 2.5.1. Global Healthcare Spending
    • 2.5.2. Spending on Healthcare and Pharmaceuticals
    • 2.5.3. Spending on Diagnostics
    • 2.5.4. Important Role of Insurance for Medical Services

3. Market Overview

  • 3.1. Players in a Dynamic Market
    • 3.1.1. Academic Research Lab
    • 3.1.2. Diagnostic Test Developer
    • 3.1.3. Instrumentation Supplier
    • 3.1.4. Chemical/Reagent Supplier
    • 3.1.5. Pathology Supplier
    • 3.1.6. Independent Clinical Laboratory
    • 3.1.7. Public National/regional Laboratory
    • 3.1.8. Hospital Laboratory
    • 3.1.9. Physicians Office Lab (POLS)
    • 3.1.10. Audit Body
    • 3.1.11. Certification Body
  • 3.2. Oncogenomics
    • 3.2.1. Carcinogenesis
    • 3.2.2. Chromosomes, Genes and Epigenetics
      • 3.2.2.1. Chromosomes
      • 3.2.2.2. Genes
      • 3.2.2.3. Epigenetics
    • 3.2.3. Cancer Genes
    • 3.2.4. Germline vs Somatic
    • 3.2.5. Gene Panels, Single Gene Assays and Multiplexing
    • 3.2.6. Genomic Profiling
    • 3.2.7. The Comprehensive Assay
    • 3.2.8. Changing Clinical Role
    • 3.2.9. The Cancer Screening Market Opportunity
  • 3.3. Cancer Management vs. Diagnosis
    • 3.3.1. The Role of Risk Assessment
    • 3.3.2. Diagnosis
    • 3.3.3. Managing
    • 3.3.4. Monitoring
  • 3.4. Phases of Adoption - Looking into The Future
  • 3.5. Structure of Industry Plays a Part
    • 3.5.1. Hospital Testing Share
    • 3.5.2. Economies of Scale
      • 3.5.2.1. Hospital vs. Central Lab
    • 3.5.3. Physician Office Lab's
    • 3.5.4. Physician's and POCT
  • 3.6. Currently Available Large Comprehensive Assays
  • 3.7. Pricing Profiling vs. Whole Exome (or Genome) Sequencing
    • 3.7.1. Medicare Profile Pricing
    • 3.7.2. Whole Exome Sequencing

4. Market Trends

  • 4.1. Factors Driving Growth
    • 4.1.1. Level of Care
    • 4.1.2. Companion Dx
    • 4.1.3. Immuno-oncology
    • 4.1.4. Liability
    • 4.1.5. The Aging Effect
  • 4.2. Factors Limiting Growth
    • 4.2.1. State of knowledge
    • 4.2.2. Genetic Blizzard
    • 4.2.3. Protocol Resistance
    • 4.2.4. Regulation and coverage
  • 4.3. Instrumentation and Automation
    • 4.3.1. Instruments Key to Market Share
    • 4.3.2. Bioinformatics Plays a Role
  • 4.4. Diagnostic Technology Development
    • 4.4.1. Next Generation Sequencing Fuels a Revolution
    • 4.4.2. Single Cell Genomics Changes the Picture
    • 4.4.3. Pharmacogenomics Blurs Diagnosis and Treatment
    • 4.4.4. CGES Testing, A Brave New World
    • 4.4.5. Biochips/Giant magneto resistance based assay

5. Cancer Panels & Profiles Recent Developments

  • 5.1. Recent Developments - Importance and How to Use This Section
    • 5.1.1. Importance of These Developments
    • 5.1.2. How to Use This Section
  • 5.2. Labcorp Completes Acquisition of Oncology Testing Assets
  • 5.3. QIAGEN Acquires Genoox
  • 5.4. Illumina Genomic Profiling Test Receives Japan Approval
  • 5.5. Otsuko Launches the First-in-Japan Comprehensive Genomic Profiling Assay
  • 5.6. Foundation Medicine, Fulgent Genetics to Launch Germline Testing
  • 5.7. Advanced Genomics APAC, 3BIGS Partner on Cancer Testing
  • 5.8. Lucence Assay Gets Coverage for Advanced Solid Tumors
  • 5.9. Foundation Medicine, AnHeart Therapeutics to Develop CDx for NSCLC Therapy
  • 5.10. Roche CGP Assay Shows Concordance With Other NGS-Based Assays
  • 5.11. Precede Biosciences Emerges From Stealth With $57M
  • 5.12. Geneseeq Nabs CE Marks for Cancer Test Kits
  • 5.13. Realm IDx Profiling Test Gets National Health Coverage in Japan
  • 5.14. Foundation Medicine, Merck KGaA to Collaborate on Companion Diagnostics
  • 5.15. Guardant Health Secures Coverage for Liquid Biopsy Profiling Test
  • 5.16. Myriad Genetics, Intermountain Precision Genomics Obtain NY Certification for Tumor Profiling
  • 5.17. Cota, Genomic Testing Coop Ink Oncology Partnership
  • 5.18. Euformatics, ViennaLab, Oncompass Win Liquid Biopsy Development Contract
  • 5.19. Prenetics' Cancer Profiling Test Receives FDA Clearance
  • 5.20. Genetic Profiling May Identify Patients Who Do Not Need Radiation Therapy
  • 5.21. Thermo Fisher Introduces Homologous Score for Cancer Profiling
  • 5.22. Genomic Test IDs Cancer Cells Early
  • 5.23. Caris Life Sciences to Offer Molecular Profiling Services
  • 5.24. Geneseeq to Build Lab for Cancer Profiling in Brazil
  • 5.25. Genetron Health Adds New Assays to Pipeline
  • 5.26. Illumina Obtains CE-IVD Marking for TSO Comprehensive Assay
  • 5.27. Guardant Health Receives Medicare Coverage for Guardant360 TissueNext(TM) Test
  • 5.28. Cancer Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
  • 5.29. Thermo Fisher, Oncocyte Ink Deal for Cancer IVDs
  • 5.30. Local Cancer Genomic Profiling Options Grow, Though Central Labs Will Likely Keep Major Role
  • 5.31. Labcorp, CCORN Partner for Precision Oncology
  • 5.32. Dante Labs Acquires Cambridge Cancer Genomics
  • 5.33. Celemics, Strand Partner on Integrated Platform for NGS Analysis
  • 5.34. Myriad Genetics Recalibrates Breast Cancer Panel for All Ancestries
  • 5.35. Burning Rock Revenues Rise
  • 5.36. Caris Life Sciences to Expand Liquid Biopsy Testing
  • 5.37. OncoDiag Announces Multiplex Test for Bladder Cancer Recurrence
  • 5.38. Intermountain and Myriad Combine Test Offering
  • 5.39. Illumina, Geneseeq to Offer Cancer Testing Kits in China
  • 5.40. Exact Sciences to Offer End-to-End Cancer Testing
  • 5.41. Guardant Health Turns to Tumor Tissue Sequencing
  • 5.42. Tempus Inks Oncology Testing Collaboration With Bayer
  • 5.43. Biocartis Collaborating With GeneproDx, Endpoint Health on Tests for Idylla Platform
  • 5.44. Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
  • 5.45. Metastatic Cancer Markers Identified in Clinical WGS Study
  • 5.46. Stitch Bio Bets on CRISPR Tech
  • 5.47. Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • 5.48. Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
  • 5.49. Progress, Challenges in Liquid Biopsy Reimbursement
  • 5.50. Israeli Startup Curesponse Raises $6M
  • 5.51. Invitae, ArcherDX Merge to Advance Precision Oncology Offerings
  • 5.52. MD Anderson Precision Oncology Decision Support to Use Philips' Informatics Solution
  • 5.53. NeoGenomics, Lilly Oncology Partner for Thyroid Cancer Testing Program
  • 5.54. Germline Results Guides Precision Therapy in Advanced Cancer
  • 5.55. FDA Clears Cancer Genomic Profiling Kit From Personal Genome Diagnostics
  • 5.56. ArcherDX, Premier Collaborate to Evaluate Genomic Sequencing Assay for Cancers
  • 5.57. Labs Reporting Cancer Risk Mutations from Tumor Testing
  • 5.58. Users Begin Integrating Genomics Data for Clinical Decision Support
  • 5.59. Fujitsu Improves Efficiency in Cancer Genomic Medicine

6. Profiles of Key Players

  • 6.1. 10x Genomics, Inc.
  • 6.2. Abbott Laboratories
  • 6.3. AccuraGen Inc.
  • 6.4. Adaptive Biotechnologies
  • 6.5. Admera Health, LLC
  • 6.6. Aethlon Medical
  • 6.7. Agilent
  • 6.8. Amoy Diagnostics Co., Ltd.
  • 6.9. Anchor Dx
  • 6.10. ANGLE plc
  • 6.11. ARUP Laboratories
  • 6.12. AVIVA Systems Biology
  • 6.13. Baylor Miraca Genetics Laboratories
  • 6.14. Beckman Coulter Diagnostics (Danaher)
  • 6.15. Becton, Dickinson and Company
  • 6.16. BGI Genomics Co. Ltd
  • 6.17. Bioarray Genetics
  • 6.18. Biocartis
  • 6.19. Biocept, Inc.
  • 6.20. Biodesix Inc.
  • 6.21. BioFluidica
  • 6.22. BioGenex
  • 6.23. BioIVT
  • 6.24. Biolidics Ltd
  • 6.25. bioMerieux Diagnostics
  • 6.26. Bioneer Corporation
  • 6.27. Bio-Rad Laboratories, Inc
  • 6.28. Bio-Reference Laboratories
  • 6.29. Bio-Techne
  • 6.30. Bioview
  • 6.31. Bristol-Myers Squibb
  • 6.32. Burning Rock
  • 6.33. C2i Genomics
  • 6.34. Cardiff Oncology
  • 6.35. Caris Molecular Diagnostics
  • 6.36. Castle Biosciences, Inc.
  • 6.37. Celemics
  • 6.38. CellMax Life
  • 6.39. Cepheid (Danaher)
  • 6.40. Charles River Laboratories
  • 6.41. Circulogene
  • 6.42. Clearbridge Biomedics
  • 6.43. Clinical Genomics
  • 6.44. Cytolumina Technologies Corp.
  • 6.45. Datar Cancer Genetics Limited
  • 6.46. Diagnologix LLC
  • 6.47. Diasorin S.p.A.
  • 6.48. Element Biosciences
  • 6.49. Enzo Biochem
  • 6.50. Epic Sciences
  • 6.51. Epigenomics AG
  • 6.52. Eurofins Scientific
  • 6.53. Exact Sciences
  • 6.54. Fabric Genomics
  • 6.55. Fluxion Biosciences (Cell Microsystems)
  • 6.56. Freenome
  • 6.57. FUJIFILM Wako Diagnostics
  • 6.58. Fujirebio
  • 6.59. GeneDx Holdings
  • 6.60. GeneFirst Ltd.
  • 6.61. Genetic Technologies Ltd.
  • 6.62. Genetron Holdings
  • 6.63. GenomOncology
  • 6.64. GILUPI Nanomedizin
  • 6.65. Guardant Health
  • 6.66. HansaBiomed
  • 6.67. HTG Molecular Diagnostics
  • 6.68. iCellate
  • 6.69. ICON PLC
  • 6.70. Illumina
  • 6.71. Incell Dx
  • 6.72. Inivata
  • 6.73. Invitae Corporation
  • 6.74. Invivogen
  • 6.75. Invivoscribe
  • 6.76. J&J Innovative Medicine
  • 6.77. KEW
  • 6.78. Lucence Health
  • 6.79. Lunglife AI Inc
  • 6.80. MDNA Life SCIENCES, Inc.
  • 6.81. MDx Health
  • 6.82. Menarini Silicon Biosystems
  • 6.83. Mesa Laboratories, Inc.
  • 6.84. Millipore Sigma
  • 6.85. Miltenyi Biotec
  • 6.86. miR Scientific
  • 6.87. Myriad Genetics
  • 6.88. Nanostring
  • 6.89. NantHealth, Inc.
  • 6.90. Natera
  • 6.91. NeoGenomics
  • 6.92. NGeneBio
  • 6.93. Novogene
  • 6.94. Oncimmune
  • 6.95. Oncocyte
  • 6.96. OncoDNA
  • 6.97. OraLiva
  • 6.98. Oxford Nanopore Technologies
  • 6.99. Panagene
  • 6.100. Personalis
  • 6.101. Perthera
  • 6.102. PGDx (Labcorp)
  • 6.103. Precipio
  • 6.104. PrecisionMed
  • 6.105. Predictive Oncology
  • 6.106. Prenetics
  • 6.107. Promega
  • 6.108. Qiagen
  • 6.109. QuidelOrtho
  • 6.110. Rarecells SAS
  • 6.111. RareCyte
  • 6.112. Revvity
  • 6.113. Roche Diagnostics
  • 6.114. Screencell
  • 6.115. Sherlock Biosciences
  • 6.116. Siemens Healthineers
  • 6.117. simfo GmbH
  • 6.118. Singlera Genomics Inc.
  • 6.119. Singular Genomics
  • 6.120. Singulomics
  • 6.121. SkylineDx
  • 6.122. Standard BioTools
  • 6.123. Stilla Technologies
  • 6.124. Sysmex Inostics
  • 6.125. Tempus Labs, Inc.
  • 6.126. Thermo Fisher Scientific
  • 6.127. Todos Medical
  • 6.128. Ultima Genomics
  • 6.129. Variantyx
  • 6.130. Vela Diagnostics
  • 6.131. Veracyte
  • 6.132. VolitionRX
  • 6.133. Vortex Biosciences

7. The Global Market for Cancer Gene Panels and Profiles

  • 7.1. Global Market Overview by Country
    • 7.1.1. Table - Global Market by Country
    • 7.1.2. Chart - Global Market by Country
  • 7.2. Global Market by Cancer Type - Overview
    • 7.2.1. Table - Global Market by Cancer Type
    • 7.2.2. Chart - Global Market by Cancer Type - Base/Final Year Comparison
    • 7.2.3. Chart - Global Market by Cancer Type - Base Year
    • 7.2.4. Chart - Global Market by Cancer Type - Final Year
    • 7.2.5. Chart - Global Market by Cancer Type - Share by Year
    • 7.2.6. Chart - Global Market by Cancer Type - Segment Growth
  • 7.3. Global Market by Application - Overview
    • 7.3.1. Table - Global Market by Application
    • 7.3.2. Chart - Global Market by Application - Base/Final Year Comparison
    • 7.3.3. Chart - Global Market by Application - Base Year
    • 7.3.4. Chart - Global Market by Application - Final Year
    • 7.3.5. Chart - Global Market by Application - Share by Year
    • 7.3.6. Chart - Global Market by Application - Segment Growth
  • 7.4. Global Market by Tissue - Overview
    • 7.4.1. Table - Global Market by Tissue
    • 7.4.2. Chart - Global Market by Tissue - Base/Final Year Comparison
    • 7.4.3. Chart - Global Market by Tissue - Base Year
    • 7.4.4. Chart - Global Market by Tissue - Final Year
    • 7.4.5. Chart - Global Market by Tissue - Share by Year
    • 7.4.6. Chart - Global Market by Tissue - Segment Growth
  • 7.5. Global Market Germline & Somatic - Overview
    • 7.5.1. Table - Global Market Germline & Somatic
    • 7.5.2. Chart - Global Market Germline & Somatic - Base/Final Year Comparison
    • 7.5.3. Chart - Global Market Germline & Somatic - Base Year
    • 7.5.4. Chart - Global Market Germline & Somatic - Final Year
    • 7.5.5. Chart - Global Market Germline & Somatic - Share by Year
    • 7.5.6. Chart - Global Market Germline & Somatic - Segment Growth

8. Global Cancer Gene Panels & Profiles Markets - By Type of Cancer

  • 8.1. Comprehensive Panels & Profiles
    • 8.1.1. Table Comprehensive Testing - by Country
    • 8.1.2. Chart - Comprehensive Testing Growth
  • 8.2. Breast Cancer Gene Testing
    • 8.2.1. Table Breast Cancer Gene Testing - by Country
    • 8.2.2. Chart - Breast Cancer Testing Growth
  • 8.3. Colorectal Cancer Gene Testing
    • 8.3.1. Table Colorectal Cancer Gene Testing - by Country
    • 8.3.2. Chart - Colorectal Cancer Gene Testing Growth
  • 8.4. Gynecological Cancer Gene Testing
    • 8.4.1. Table Gynecological Cancer Gene Testing - by Country
    • 8.4.2. Chart - Gynecological Cancer Gene Testing Growth
  • 8.5. Blood Cancer Gene Testing
    • 8.5.1. Table Blood Cancer Gene Testing - by Country
    • 8.5.2. Chart - Blood Cancer Gene Testing Growth
  • 8.6. Prostate Cancer Gene Testing
    • 8.6.1. Table Prostate Cancer Gene Testing - by Country
    • 8.6.2. Chart - Prostate Cancer Testing Growth
  • 8.7. Lung Cancer Gene Testing
    • 8.7.1. Table Lung Cancer Gene Testing - by Country
    • 8.7.2. Chart - Lung Cancer Gene Testing Growth
  • 8.8. Other Cancer Gene Testing
    • 8.8.1. Table Other Cancer Gene Testing - by Country
    • 8.8.2. Chart - Other Cancer Gene Testing Growth

9. Global Cancer Gene Panels & Profiles Markets - By Type of Application

  • 9.1. Clinical Testing
    • 9.1.1. Table Clinical Testing - by Country
    • 9.1.2. Chart - Clinical Testing Growth
  • 9.2. Pharmaceutical Testing
    • 9.2.1. Table Pharmaceutical Testing - by Country
    • 9.2.2. Chart - Pharmaceutical Testing Growth
  • 9.3. Research Testing
    • 9.3.1. Table Research Testing - by Country
    • 9.3.2. Chart - Research Testing Growth

10. Global Cancer Gene Panels & Profiles Markets - By Tissue Type

  • 10.1. Solid Tissue
    • 10.1.1. Table Solid Tissue Testing - by Country
    • 10.1.2. Chart - Solid Tissue Testing Growth
  • 10.2. Liquid Tissue Testing
    • 10.2.1. Table Liquid Tissue Testing - by Country
    • 10.2.2. Chart - Liquid Tissue Testing Growth

11. Global Cancer Gene Testing Markets - Germline and Somatic

  • 11.1. Global Market Somatic
    • 11.1.1. Table Somatic - by Country
    • 11.1.2. Chart - Somatic Testing Growth
  • 11.2. Global Market Germline
    • 11.2.1. Table Germline - by Country
    • 11.2.2. Chart - Germline Testing Growth

12. Potential Market Opportunity Sizes

  • 12.1. Potential Cancer Screening by Country: Lung, Breast & Colorectal
  • 12.2. Potential Cancer Screening by Country: Prostate, Other Cancer & All Cancer
  • 12.3. Potential Market Size - Cancer Diagnosis
  • 12.4. Potential Market Size - Therapy Selection

13. Appendices

  • 13.1. Growth of Approved IVD Test Menu
  • 13.2. Growth of Approved Average IVD Test Fee
  • 13.3. The Most Used IVD Assays
  • 13.4. The Highest Grossing Assays
  • 13.5. Laboratory Fees Schedule

Table of Tables

  • Table 1: Market Players by Type
  • Table 2: The Base Pairs
  • Table 3: Current Assays
  • Table 4: Relevant Pricing Table
  • Table 5: Five Factors Driving Growth
  • Table 6: Four Factors Limiting Growth
  • Table 7: Key Diagnostic Laboratory Technology Trends
  • Table 8: Next Generation Sequencing Technologies - Speed and Cost
  • Table 9 - Global Cancer Panel Market by Region
  • Table 10: Global Market by Cancer Type
  • Table 11: Global Market by Application
  • Table 12: Global Market by Tissue
  • Table 13: Global Market Germline & Somatic
  • Table 14: Comprehensive Testing by Country
  • Table 15: Breast Cancer Gene Testing by Country
  • Table 16: Colorectal Cancer Gene Testing by Country
  • Table 17: Gynecological Cancer Testing by Country
  • Table 18: Blood Cancer Gene Testing by Country
  • Table 19: Prostate Cancer Gene Testing by Country
  • Table 20: Lung Cancer Gene Testing by Country
  • Table 21: Other Cancer Gene Testing by Country
  • Table 22: Clinical Testing by Country
  • Table 23: Pharmaceutical Testing by Country
  • Table 24: Research Testing by Country
  • Table 25: Solid Tissue Testing by Country
  • Table 26: Liquid Tissue Testing by Country
  • Table 27: Somatic by Country
  • Table 28: Germline by Country
  • Table 29: Potential Screening Market: Lung, Breast & Colorectal
  • Table 30: Potential Screening Market: Prostate, Other & All
  • Table 31: Potential Cancer Diagnosis Market Size
  • Table 32: Potential Cancer Management Market Size
  • Table 33: The Most Common Assays
  • Table 34: Largest Revenue Assays
  • Table 35: Clinical Lab Fee Schedule

Table of Figures

  • Figure 1: VistSeq Hereditary Cancer Panel
  • Figure 2: Global Healthcare Spending
  • Figure 3: The Road to Diagnostics
  • Figure 4: The Genomic Progression of Cancer
  • Figure 5: DNA Strands and Chromosomes
  • Figure 6: Karyogram of Human Chromosomes
  • Figure 7: Size of Various Genomes
  • Figure 8: Germline vs Somatic Mutations
  • Figure 9: Comparing Genomic Diagnostic and Traditional Testing
  • Figure 10: The Changing Age of The World's Population
  • Figure 11: Health Care Consumption by Age
  • Figure 12: Cancer Incidence - Age at Diagnosis
  • Figure 13: Base Year Country Global Share
  • Figure 14: Global Market by Cancer - Base vs. Final Year
  • Figure 15: Cancer Panel Market Base Year
  • Figure 16: Cancer Panel Market Final Year
  • Figure 17: Cancer Type Share by Year
  • Figure 18: Cancer Type Segment Growth
  • Figure 19: Global Market by Cancer - Base vs. Final Year
  • Figure 20: Cancer Panel Market Base Year
  • Figure 21: Cancer Panel Market Final Year
  • Figure 22: Application Share by Year
  • Figure 23: Application Segment Growth
  • Figure 24: Global Market by Cancer - Base vs. Final Year
  • Figure 25: Cancer Panel Market Base Year
  • Figure 26: Cancer Panel Market Final Year
  • Figure 27: Tissue Share by Year
  • Figure 28: Tissue Segment Growth
  • Figure 29: Germline & Somatic - Base vs. Final Year
  • Figure 30: Germline & Somatic Market Base Year
  • Figure 31: Germline & Somatic Market Final Year
  • Figure 32: Germline & Somatic Share by Year
  • Figure 33: Germline & Somatic Segment Growth
  • Figure 34: Comprehensive Testing Growth
  • Figure 35: Breast Cancer Testing Growth
  • Figure 36: Colorectal Cancer Gene Testing Growth
  • Figure 37: Gynecological Cancer Testing Growth
  • Figure 38: Blood Cancer Gene Testing Growth
  • Figure 39: Prostate Cancer Gene Testing Growth
  • Figure 40: Lung Cancer Gene Testing Growth
  • Figure 41: Other Cancer Gene Testing Growth
  • Figure 42: Clinical Testing Growth
  • Figure 43: Pharmaceutical Testing Growth
  • Figure 44: Research Testing Growth
  • Figure 45: Solid Tissue Testing Growth
  • Figure 46: Liquid Tissue Testing Growth
  • Figure 47: Somatic Testing Growth
  • Figure 48: Germline Testing Growth
  • Figure 49: IVD Test Menu Growth
  • Figure 50: IVD Test Average Fees - A Ten Year View